Akebia Therapeutics vs Puma Biotechnology
Akebia Therapeutics and Puma Biotechnology are similar in size: $236m and $228m of revenue in their latest fiscal years. Akebia Therapeutics grew faster (47.5% against -0.9%). Puma Biotechnology kept more of each dollar of sales as profit: a net margin of 13.6% against -2.3%.
| Latest fiscal year | Akebia TherapeuticsAKBA, 2025 | Puma BiotechnologyPBYI, 2025 |
|---|---|---|
| Revenue | $236m | $228m |
| Revenue growth | 47.5% | -0.9% |
| Net income | −$5.3m | $31.1m |
| Operating margin | — | 16.3% |
| Net margin | -2.3% | 13.6% |
| Return on equity | — | 28.0% |
| Free cash flow | $67.7m | $41.7m |
| Cash | $185m | $29.6m |
| Total debt | $52.4m | $22.7m |
| Debt to equity | — | 17.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 194 | 179 |
| Market value | $193m | $521m |
| Price vs our value range | — | Below our value range |
| Moat score | 23 (Weak) | 47 (Moderate) |
| Insider trades, 12 months | 1 buys, 16 sales | 0 buys, 17 sales |